© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
February 23, 2022
Treatment with tivozanib was associated with a fivefold increased likelihood of experiencing long-term progression-free survival compared to treatment with sorafenib.
February 20, 2022
First-line tivozanib in patients with metastatic renal cell carcinoma was reported to be safe, tolerable, and capable of producing similar clinical activity as other tyrosine kinase inhibitors used in this setting.
September 18, 2021
The retrospective cohort study assessed outcomes in patients with advanced renal cell carcinoma who received cabozantinib or axitinib in the second-line setting or beyond.
February 11, 2021
The novel agent eganelisib led to higher response rates with nivolumab in PD-L1–low patients with metastatic urothelial carcinoma.